WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/086469    International Application No.:    PCT/US2006/004424
Publication Date: 17.08.2006 International Filing Date: 08.02.2006
A61K 39/395 (2006.01), C07K 16/18 (2006.01)
Applicants: GENZYME CORPORATION; 500 Kendall Square, Cambridge, MA 02142 (US) (For All Designated States Except US).
LEDBETTER, Steven R. [US/US]; (US) (For US Only).
HART, Celia P. [GB/FR]; (FR).
HOLGATE, Robert G. [GB/GB]; (GB).
JERMUTUS, Lutz U. [DE/GB]; (GB).
BUCHANAN, Catriona L. [GB/GB]; (GB).
DUNCAN, Alexander R. [GB/GB]; (GB).
FINCH, Donna K. [GB/GB]; (GB)
Inventors: LEDBETTER, Steven R.; (US).
HART, Celia P.; (FR).
HOLGATE, Robert G.; (GB).
JERMUTUS, Lutz U.; (GB).
BUCHANAN, Catriona L.; (GB).
DUNCAN, Alexander R.; (GB).
FINCH, Donna K.; (GB)
Agent: GUNNISON, Jane, T.; FISH & NEAVE IP GROUP, ROPES & GRAY LLP, 1211 Avenue Of The Americas, New York, New York 10036-8704 (US)
Priority Data:
60/651,343 08.02.2005 US
Abstract: front page image
(EN)The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF&bgr;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF&bgr;1, TGF&bgr;2, and TGF&bgr;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
(FR)La présente invention concerne des molécules d'anticorps, en particulier des molécules d'anticorps qui fixent le facteur de croissance transformant bêta (TGF$g(b)), et leurs applications. L'invention concerne plus particulièrement des molécules d'anticorps qui fixent et, de préférence, neutralisent, TGF$g(b)1, TGF$g(b)2 et TGF$g(b)3, des molécules d'anticorps dites « pan-spécifiques », et leurs applications. Les modes de réalisation préférés de la présente invention concernent des molécules d'anticorps, à savoir des anticorps totaux (des IgG, tels que IgG1 ou IgG4, par exemple) ou des fragments d'anticorps (scFv, Fab, dAb, par exemple).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)